NEW YORK — EKF Diagnostics said on Thursday that it has signed a three-year distribution deal for its point-of-care Quo-Test HbA1c analyzer in the Middle East and Africa with Tosoh Europe.
The desktop system, which received 510(k) clearance from the US Food and Drug Administration last year, is designed to measure glycated hemoglobin levels in whole blood for use in the monitoring and management of diabetes. Cardiff, UK-based EKF said the system provides results within four minutes.
Under the terms of the deal, Tosoh Europe — a unit of Tokyo-based Tosoh — will distribute the system in the Middle East and Africa for three years, with a rolling one-year renewal and an option to extend the arrangement into Europe Union markets.
Additional terms were not disclosed.